购物车
- 全部删除
- 您的购物车当前为空
MI136 是 menin-MLL(PPI) 蛋白互作的抑制剂,其 IC50值为31 nM,Kd 值为23.6 nM。它可抑制 DHT 诱导的雄激素受体 (AR) 靶基因的表达,有用于去势抵抗性肿瘤的潜能。
为众多的药物研发团队赋能,
让新药发现更简单!
MI136 是 menin-MLL(PPI) 蛋白互作的抑制剂,其 IC50值为31 nM,Kd 值为23.6 nM。它可抑制 DHT 诱导的雄激素受体 (AR) 靶基因的表达,有用于去势抵抗性肿瘤的潜能。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 368 | 现货 | |
2 mg | ¥ 527 | 现货 | |
5 mg | ¥ 872 | 现货 | |
10 mg | ¥ 1,490 | 现货 | |
25 mg | ¥ 2,960 | 现货 | |
50 mg | ¥ 4,390 | 现货 | |
100 mg | ¥ 6,280 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 962 | 现货 |
产品描述 | MI-136 inhibits expression of androgen receptor (AR) target genes that DHT induced. |
体外活性 | MI-136是一种之前描述的抑制剂的变体,能特异性抑制menin-MLL相互作用。AR阳性细胞系如VCaP、LNCaP和22RV1对MI-136敏感。MI-136的治疗还抑制了AR刺激后与ASH2L结合的基因表达。使用MI-136治疗能诱导VCaP细胞凋亡,通过PARP(cPARP)切割作为证据,并阻断DHT诱导的AR依赖性细胞系(LNCaP和VCaP)的细胞增殖。MI-136对细胞增殖的效果与MDV-3100相似,MDV-3100是一种获FDA批准的用于治疗难治性前列腺癌患者的第二代抗雄性激素。 |
体内活性 | 对携带VCaP肿瘤的小鼠进行MI-136(40 mg/kg)治疗,可以使肿瘤体积有适度但显著的减少,而对小鼠体重无影响[1]。 |
激酶实验 | HSP90 binding, ATPase, and selectivity profiling assays: The potency of HSP90 inhibitors for HSP90α, HSP90β, and Grp94 is determined by AlphaScreen competition binding assays, and activity against TRAP-1 is assessed by an ATPase assay. |
细胞实验 | To assess the effect of MI-136 on AR signaling, VCaP cells are treated with DMSO or 5 μM MI-136 for 48 hours. Cells are serum starved by replacing the media with DMEM containing 5% charcoal-striped serum and MI-136 for 48 hrs. Cells are then stimulated with 10 nM DHT for 12 hrs and RNA is isolated and processed for expression microarrays. (Only for Reference) |
分子量 | 470.51 |
分子式 | C23H21F3N6S |
CAS No. | 1628316-74-4 |
Smiles | FC(F)(F)Cc1cc2c(NC3CCN(Cc4ccc5[nH]c(cc5c4)C#N)CC3)ncnc2s1 |
密度 | 1.45 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | H2O: < 1 mg/mL (insoluble or slightly soluble) Ethanol: 87 mg/mL (184.9 mM) DMSO: 87 mg/mL (184.9 mM) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容